Antipsychotic drugs predominate in pharmacotherapy of nursing home residents with dementia

Pharmacopsychiatry

Volumn 45, Issue 5, 2012, Pages 182-188

  Huber, M ^a   Kolzsch M ^a   Rapp, M A ^a   Wulff, I ^a   Kalinowski, S ^a   Bolbrinker, J ^a   Hofmann, W ^a   Scholze, J ^a   Drager D ^a   Kreutz, R ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

anti dementia drugs; antipsychotic drugs; dementia; elderly; nursing home residents

Indexed keywords

ANALGESIC AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHLORPROTHIXENE; CHOLINESTERASE INHIBITOR; DONEPEZIL; FLUSPIRILENE; GALANTAMINE; GINKGO BILOBA EXTRACT; HALOPERIDOL; HYPNOTIC AGENT; LORAZEPAM; MELPERONE; MEMANTINE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PIMOZIDE; PIPAMPERONE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SULPIRIDE; TIAPRIDE; ZOLPIDEM; ZOPICLONE; ZOTEPINE;

AGED; ALZHEIMER DISEASE; ARTICLE; COHORT ANALYSIS; DEMENTIA; DIFFUSE LEWY BODY DISEASE; FEMALE; GERMANY; HUMAN; MALE; MULTIINFARCT DEMENTIA; NURSING HOME PATIENT; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYMPTOM;

AGED; AGED, 80 AND OVER; BEHAVIORAL SYMPTOMS; DEMENTIA; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; DRUG UTILIZATION REVIEW; FEMALE; GERMANY; HOMES FOR THE AGED; HUMANS; MALE; MEDICATION THERAPY MANAGEMENT; NURSING HOMES; PRESCRIPTION DRUGS; PSYCHOTROPIC DRUGS;

EID: 84864279277     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0031-1301285     Document Type: Article

References (48)

1. Sink K M, Holden K F, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA: 2005; 293 596 608 (Pubitemid 40171242)
2. Small G W, Rabins P V, Barry P P et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA: 1997; 278 1363 1371 (Pubitemid 27449698)
3. Fratiglioni L, De R D, Aguero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging: 1999; 15 365 375 (Pubitemid 29527871)
4. Tjia J, Rothman M R, Kiely D K et al. Daily medication use in nursing home residents with advanced dementia. J Am Geriatr Soc: 2010; 58 880 888
5. Cavalieri M, Enzinger C, Petrovic K et al. Vascular dementia and Alzheimer's disease are we in a dead-end road? Neurodegener Dis: 2010; 7 122 126
6. Parsons C, Briesacher B A, Givens J L et al. Cholinesterase inhibitor and memantine use in newly admitted nursing home residents with dementia. J Am Geriatr Soc: 2011; 59 1253 1259
7. Ballard C G, Gauthier S, Cummings J L et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol: 2009; 5 245 255
8. Cummings J L, Mackell J, Kaufer D. Behavioral effects of current Alzheimer's disease treatments: a descriptive review. Alzheimers Dement: 2008; 4 49 60
9. Snowden M, Sato K, Roy-Byrne P. Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature. J Am Geriatr Soc: 2003; 51 1305 1317 (Pubitemid 37093582)
10. Franchi C, Lucca U, Tettamanti M et al. Cholinesterase inhibitor use in Alzheimer's disease: the EPIFARM-Elderly Project. Pharmacoepidemiol Drug Saf: 2011; 20 497 505
11. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt H P et al. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ: 2005; 331 7512 321 327
12. Lanctot K L, Herrmann N, Yau K K et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ: 2003; 169 557 564 (Pubitemid 37174596)
13. Majic T, Pluta J P, Mell T et al. The pharmacotherapy of neuropsychiatric symptoms of dementia: a cross-sectional study in 18 homes for the elderly in Berlin. Dtsch Arztebl Int: 2010; 107 320 327
14. O'Brien J. Antipsychotics for people with dementia. BMJ: 2008; 337 a602
15. Petek S M, Cedilnik G E. Psychotropic medication use among elderly nursing home residents in Slovenia: cross-sectional study. Croat Med J: 2011; 52 16 24
16. Schneider L S, Tariot P N, Dagerman K S et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med: 2006; 355 1525 1538 (Pubitemid 44547805)
17. Ballard C, Hanney M L, Theodoulou M et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol: 2009; 8 151 157
18. Trifiro G, Verhamme K M, Ziere G et al. All-cause mortality associated with atypical and typical antipsychotics in demented outpatients. Pharmacoepidemiol Drug Saf: 2007; 16 538 544 (Pubitemid 46824275)
19. Schneider L S, Dagerman K S, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA: 2005; 294 1934 1943 (Pubitemid 41464695)
20. World Health Organization Anatomical Therapeutic Chemical (ATC) classification system.
21. th Revision.
22. Federal Statistical Office of Germany Pflegestatistik 2009 (Statistical Analysis about Nursing and Care)
23. Azermai M, Elseviers M, Petrovic M et al. Geriatric drug utilisation of psychotropics in Belgian nursing homes. Hum Psychopharmacol Mar: 2011; 10.1002/hup.1160
24. Nishtala P S, McLachlan A J, Bell J S et al. Determinants of antipsychotic medication use among older people living in aged care homes in Australia. Int J Geriatr Psychiatry: 2010; 25 449 457
25. Azermai M, Elseviers M, Petrovic M et al. Assessment of antipsychotic prescribing in Belgian nursing homes. Int Psychogeriatr: 2011; 23 1240 1248
26. Beers M H, Ouslander J G, Fingold S F et al. Inappropriate medication prescribing in skilled-nursing facilities. Ann Intern Med: 1992; 117 684 689
27. Doshi J A, Shaffer T, Briesacher B A. National estimates of medication use in nursing homes: findings from the 1997 medicare current beneficiary survey and the 1996 medical expenditure survey. J Am Geriatr Soc: 2005; 53 438 443 (Pubitemid 41623522)
28. Gruber-Baldini A L, Stuart B, Zuckerman I H et al. Treatment of dementia in community-dwelling and institutionalized medicare beneficiaries. J Am Geriatr Soc: 2007; 55 1508 1516 (Pubitemid 47508513)
29. Magaziner J, German P, Zimmerman S I et al. The prevalence of dementia in a statewide sample of new nursing home admissions aged 65 and older: diagnosis by expert panel. Epidemiology of Dementia in Nursing Homes Research Group. Gerontologist: 2000; 40 663 672 (Pubitemid 32010251)
30. Qaseem A, Snow V, Cross J T et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med: 2008; 148 370 378 (Pubitemid 351665468)
31. Lucca U, Nobili A, Riva E et al. Cholinesterase inhibitor use and age in the general population. Arch Neurol: 2006; 63 154 155 (Pubitemid 43063880)
32. Schoenmaker N, van Gool W A. The age gap between patients in clinical studies and in the general population: a pitfall for dementia research. Lancet Neurol: 2004; 3 627 630 (Pubitemid 39221930)
33. Holmes H M, Sachs G A, Shega J W et al. Integrating palliative medicine into the care of persons with advanced dementia: identifying appropriate medication use. J Am Geriatr Soc: 2008; 56 1306 1311
34. Alanen H M, Finne-Soveri H, Noro A et al. Use of antipsychotic medications among elderly residents in long-term institutional care: a three-year follow-up. Int J Geriatr Psychiatry: 2006; 21 288 295
35. Furniss L, Craig S K, Burns A. Medication use in nursing homes for elderly people. Int J Geriatr Psychiatry: 1998; 13 433 439 (Pubitemid 28370548)
36. Holmquist I B, Svensson B, Hoglund P. Psychotropic drugs in nursing- and old-age homes: relationships between needs of care and mental health status. Eur J Clin Pharmacol: 2003; 59 669 676 (Pubitemid 37494537)
37. Macdonald A J, Carpenter G I, Box O et al. Dementia and use of psychotropic medication in non-Elderly Mentally Infirm' nursing homes in South East England. Age Ageing: 2002; 31 58 64 (Pubitemid 34187753)
38. Finkel S. Introduction to behavioural and psychological symptoms of dementia (BPSD). Int J Geriatr Psychiatry: 2000; 15 01 S2 S4
39. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev: 2006; 01 CD003476
40. Paleacu D, Barak Y, Mirecky I et al. Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study. Int J Geriatr Psychiatry: 2008; 23 393 400 (Pubitemid 351566336)
41. Gurwitz J H, Field T S, Avorn J et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med: 2000; 109 87 94
42. FDA Food and Drug Administration Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances.
43. FDA Food and Drug Administration Boxed Warnings on Older Class of Antipsychotic Drugs.
44. EMEA - European Medicines Agency Opinion of the Committee for Medicinal Products for Human Use Pursuant to Article 5(3) of Regulation (EC) No 726/2004, on Conventional Antipsychotics
45. Molter-Bock E, Hasford J, Pfundstein T. Psychopharmacological drug treatment in Munich nursing homes. Z Gerontol Geriatr: 2006; 39 336 343 (Pubitemid 44581744)
46. Hughes C M, Lapane K L. Administrative initiatives for reducing inappropriate prescribing of psychotropic drugs in nursing homes: how successful have they been? Drugs Aging: 2005; 22 339 351 (Pubitemid 40656022)
47. Castle N G, Hanlon J T, Handler S M. Results of a longitudinal analysis of national data to examine relationships between organizational and market characteristics and changes in antipsychotic prescribing in US nursing homes from 1996 through 2006. Am J Geriatr Pharmacother: 2009; 7 143 150
48. Stevenson D G, Decker S L, Dwyer L L et al. Antipsychotic and benzodiazepine use among nursing home residents: findings from the 2004 National Nursing Home Survey. Am J Geriatr Psychiatry: 2010; 18 1078 1092